EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan

References

• Hugli O, Braun JE, Kim S, Pelletier AJ, Camargo CA Jr. United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am. J. Cardiol.96(11), 1537–1542 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas S, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Heart Fail. Clin.3(4), 381–387 (2007).
   PubMedGoogle Scholar
• Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation112(25), 3958–3968 (2005).
   PubMed Web of Science ®Google Scholar
• Kasper EK, Gerstenblith G, Hefter G et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J. Am. Coll. Cardiol.39(3), 471–480 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur. Heart J.26(7), 644–649 (2005).
   PubMed Web of Science ®Google Scholar
• Hill JA, Yancy CW, Abraham WT. Beyond diuretics: management of volume overload in acute heart failure syndromes. Am. J. Med.119(12 Suppl. 1), S37–S44 (2006).
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J. Am. Coll. Cardiol.46(10), 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Klein L, O’Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation111(19), 2454–2460 (2005).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Rossi JS, Cotts W et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch. Intern. Med.167(18), 1998 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur. Heart J.28(8), 980–988 (2007).
   PubMed Web of Science ®Google Scholar
• Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs67(6), 847–858 (2007).
   PubMed Web of Science ®Google Scholar
• Costello-Boerrigter LC, Smith WB, Boerrigter G et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Renal Physiol.290(2), F273–F278 (2006).
   PubMed Web of Science ®Google Scholar
• Verbalis JG. Vasopressin V2 receptor antagonists. J. Mol. Endocrinol.29(1), 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Ogawa H, Yamashita H et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol.105(4), 787–791 (1992).
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Nakamura S, Itoh S et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther.287(3), 860–867 (1998).
   PubMed Web of Science ®Google Scholar
• Burnett JC, Smith WB, Ouyang J, Zimmer CA, Orlandi C. Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy. J. Card. Fail.9(5 Suppl. 1), 12 (2003).
   Google Scholar
• Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation107(21), 2690–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA291(16), 1963–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC Jr. et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA297(12), 1332–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA297(12), 1319–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med.355(20), 2099–2112 (2006).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Bristow MR, Cohn JN et al.; Moxonidine Safety and Efficacy (MOXSE) Investigators. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation105, 1797–1803 (2002).
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJV, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation109, 1594–1602 (2004).
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Hung Lo K, Fasmanade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) trial. Circulation107, 3133–3140 (2003).
   PubMed Web of Science ®Google Scholar
• Rich S. Endothelin receptor blockers in cardiovascular disease. Circulation108, 2184–2190 (2003).
   PubMed Web of Science ®Google Scholar
• Coletta AP, Cleland JG. Clinical trials update highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology – WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. J. Heart Fail.3, 747–750 (2001).
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation106, 920–926 (2002).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gottlieb SS, Udelson JE et al. Vasopressin V(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am. J. Cardiol.97(7), 1064–1067 (2006).
   PubMed Web of Science ®Google Scholar
• Udelson JE, Orlandi C, Ouyang J et al. Acute hemodynamic effects of Tolvaptan, a vasopressin V2 Receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial. J. Card. Fail.13(9), 793–794 (2007).
   Google Scholar